Please assess the completion status of the following clinical trial:

Trial Title: Individualized Triple-therapy Using Boceprevir in HIV-positive Patients With Hepatitis C

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed HIV infection (anti-HIV1/2 antibody positive).~* Chronic HCV infection (anti-HCV positive, HCV-RNA detectable for \>6 months).~* HCV-GT 1 infection.~* Age ≥18 years and ≤65 years.~* No prior treatment with BOC/PEGIFN/RBV.~* CD4+ cell count \>200 cells/µL.~* Stable antiretroviral therapy (ART) including tenofovir/emtricitabine (Truvada®, Gilead) and raltegravir (Isentress®, MSD) with HIV-RNA \<50 copies/mL.~* Valid result on transient elastography or liver biopsy within 6 months prior to enrollment.~* Female patients of childbearing potential must agree to use an effective contraceptive during treatment and for 4 months after treatment has been concluded.~* Male patients or their female partners must agree to use an effective contraceptive during treatment and for 7 months after treatment has been concluded.~Exclusion Criteria:~* HCV-GT other than HCV-GT 1.~* Cirrhotic patients (as defined by METAVIR F4 in liver biopsy or liver stiffness \>12.3 kPa) with decompensated liver disease (Child-Pugh stage B/C).~* Chronic liver diseases other than hepatitis C virus infection (hepatitis B virus infection: HBsAg positivity, nonalcoholic steatohepatitis, autoimmune hepatitis, primary biliary cirrhosis, hemochromatosis, Wilson's disease, alpha-1 antitrypsin deficiency, cystic fibrosis).~* Significant cardiac disease (ejection fraction \<40% at echocardiography).~* Significant pulmonary disease (COPD stage GOLD III/IV).~* Significant renal disease (serum creatinine \>1.5 mg/dL).~* Subjects taking medication(s) that is/are highly dependent on CYP3A4/5 for clearance, and for which elevated plasma concentrations are associated with serious and/or life-threatening events such as but not limited to, orally administered midazolam, pimozide, amiodarone, flecainide, propafenone, quinidine, and ergot derivatives (dihydroergotamine, ergonovine, ergotamine, methylergonovine).~* Contraindications for boceprevir (Victrelis®, MSD), pegylated interferon alpha-2a (Pegasys®, Roche) or ribavirin (Copegus®, Roche), as listed in section 4.3 of the respective summary of product characteristics (SmPCs).~* Ongoing alcohol abuse (average daily alcohol consumption \>50g).~* Ongoing illicit drug abuse.~* Unwillingness to give written informed consent.~* Pregnancy and breastfeeding.~* Women wishing to become pregnant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- 28 weeks of treatment duration (Type: EXPERIMENTAL): All patients will receive 4 weeks of PEGIFN/RBV lead-in. Patients with undetectable HCV-RNA at treatment week 8 will be treated with 24 weeks of BOC/PEGIFN/RBV triple-therapy resulting in a total treatment duration of 28 weeks.
- 48 weeks of treatment duration (Type: EXPERIMENTAL): All patients will receive 4 weeks of PEGIFN/RBV lead-in. Patients with detectable HCV-RNA at treatment week 8 will receive 44 weeks of BOC/PEGIFN/RBV triple-therapy and a total treatment duration of 48 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).